Institution
University of South Australia
Education•Adelaide, South Australia, Australia•
About: University of South Australia is a education organization based out in Adelaide, South Australia, Australia. It is known for research contribution in the topics: Population & Poison control. The organization has 10086 authors who have published 32587 publications receiving 913683 citations. The organization is also known as: The University of South Australia & UniSA.
Topics: Population, Poison control, Health care, Mental health, Adsorption
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Two WHO-sponsored workshops were recently held to obtain a consensus view from researchers active in the field of reproductive immunology on the current status of the application of monoclonal antibodies to studies of molecular events underlying reproduction and to determine the feasibility of using this approach to identify trophoblast- or sperm-specific antigens that might represent suitable candidates for the development of antifertility vaccines.
168 citations
••
TL;DR: A suite of guanidine copolymers has been identified that represent a new class of antimicrobial polymers with high potency and low toxicity, and appear to be a balance between charge density, hydrophobic character, and polymer chain length.
168 citations
••
TL;DR: It is demonstrated that selective FASN inhibition antagonizes CRPC growth through metabolic reprogramming and results in reduced protein expression and transcriptional activity of both full-length AR (AR-FL) and AR-V7, which offers a therapeutic opportunity for mCRPC and a potential mechanism to overcome resistance to AR inhibitors.
Abstract: A hallmark of prostate cancer progression is dysregulation of lipid metabolism via overexpression of fatty acid synthase (FASN), a key enzyme in de novo fatty acid synthesis. Metastatic castration-resistant prostate cancer (mCRPC) develops resistance to inhibitors of androgen receptor (AR) signaling through a variety of mechanisms, including the emergence of the constitutively active AR variant V7 (AR-V7). Here, we developed an FASN inhibitor (IPI-9119) and demonstrated that selective FASN inhibition antagonizes CRPC growth through metabolic reprogramming and results in reduced protein expression and transcriptional activity of both full-length AR (AR-FL) and AR-V7. Activation of the reticulum endoplasmic stress response resulting in reduced protein synthesis was involved in IPI-9119–mediated inhibition of the AR pathway. In vivo, IPI-9119 reduced growth of AR-V7–driven CRPC xenografts and human mCRPC-derived organoids and enhanced the efficacy of enzalutamide in CRPC cells. In human mCRPC, both FASN and AR-FL were detected in 87% of metastases. AR-V7 was found in 39% of bone metastases and consistently coexpressed with FASN. In patients treated with enzalutamide and/or abiraterone FASN/AR-V7 double-positive metastases were found in 77% of cases. These findings provide a compelling rationale for the use of FASN inhibitors in mCRPCs, including those overexpressing AR-V7.
168 citations
••
TL;DR: In this article, the spatial distribution of mapped landscape values or values home range is related to, but not identical to, mapped place attachment, with just over half of landscape values located outside the area of placed attachment.
168 citations
••
TL;DR: Routine incorporation of beta-glucan preparations like EcoActivaduring winter may enhance macrophage function and growth rates at a time of increased disease susceptibility and little or no growth.
167 citations
Authors
Showing all 10298 results
Name | H-index | Papers | Citations |
---|---|---|---|
Andrew P. McMahon | 162 | 415 | 90650 |
Timothy P. Hughes | 145 | 831 | 91357 |
Jeremy K. Nicholson | 141 | 773 | 80275 |
Peng Shi | 137 | 1371 | 65195 |
Daniel Thomas | 134 | 846 | 84224 |
Jian Li | 133 | 2863 | 87131 |
Matthew Jones | 125 | 1161 | 96909 |
Ulrich S. Schubert | 122 | 2229 | 85604 |
Elaine Holmes | 119 | 560 | 58975 |
Arne Astrup | 114 | 866 | 68877 |
Richard Gray | 109 | 808 | 78580 |
John B. Furness | 103 | 597 | 37668 |
Thomas J. Jentsch | 101 | 238 | 32810 |
Ben W.J. Mol | 101 | 1485 | 47733 |
John C. Lindon | 99 | 488 | 44063 |